Biller Jonathan
SEC CIK 1744749 · EDGAR
BoughtSold
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 34
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-02-24 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $485.11 | -1,144 | 14.6K | -7% | -$555.0K | |
| 2026-02-26 | 2026-02-25 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $486.35 | -945 | 13.7K | -6% | -$459.6K | |
| M | 2026-02-19 | 2026-02-17+ | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $484.18 | -3,720 | 17.0K | -18% | -$1.80M |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $483.75 | -1,505 | 19.5K | -7% | -$728.0K | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +4,135 | 21.0K | +25% | $0 | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $487.76 | -2,993 | 17.8K | -14% | -$1.46M | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $499.00 | -988 | 16.8K | -6% | -$493.0K | |
| 2026-02-12 | 2026-02-11 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $460.43 | -1,925 | 20.8K | -8% | -$886.3K | |
| 2026-02-12 | 2026-02-10 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $468.41 | -1,630 | 22.7K | -7% | -$763.5K | |
| M | 2026-01-26 | 2026-01-22 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +9,068 | 21.6K | +72% | $0 |
| 2025-12-05 | 2025-12-03 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $449.00 | -347 | 15.3K | -2% | -$155.8K | |
| 2025-10-03 | 2025-10-02 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $404.21 | -694 | 15.7K | -4% | -$280.5K | |
| 2025-10-03 | 2025-10-01 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $400.00 | -1,259 | 16.3K | -7% | -$503.6K | |
| 2025-02-19 | 2025-02-18 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $455.06 | -1,657 | 17.6K | -9% | -$754.0K | |
| 2025-02-19 | 2025-02-14 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $463.46 | -1,504 | 19.3K | -7% | -$697.0K | |
| 2025-02-14 | 2025-02-12 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +4,437 | 20.8K | +27% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $467.98 | -1,632 | 19.8K | -8% | -$763.7K | |
| 2025-02-12 | 2025-02-11 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $459.87 | -3,433 | 16.3K | -17% | -$1.58M | |
| 2025-02-06 | 2025-02-04 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +4,744 | 21.4K | +28% | $0 | |
| 2024-10-03 | 2024-10-02 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $461.66 | -999 | 16.7K | -6% | -$461.2K | |
| 2024-10-03 | 2024-10-01 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $466.84 | -630 | 17.6K | -3% | -$294.1K | |
| 2024-02-13 | 2024-02-09 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $422.74 | -1,588 | 20.0K | -7% | -$671.3K | |
| 2024-02-13 | 2024-02-12 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $418.77 | -1,738 | 18.3K | -9% | -$727.8K | |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +11.0K | 16.9K | +189% | $0 |
| 2023-10-03 | 2023-09-29 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | F - Tax | $350.72 | -408 | 11.2K | -4% | -$143.1K | |
| 2023-10-03 | 2023-10-02 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | S - Sale | $346.76 | -610 | 10.6K | -5% | -$211.5K | |
| 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +6,293 | 11.6K | +119% | $0 | |
| 2022-09-21 | 2022-09-19 | VRTX | Vertex Pharmaceuticals | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +5,294 | 5,294 | New | $0 | |
| D | 2022-02-23 | 2022-02-18 | AGIO | AGIOS PHARMACEUTICALS, INC. | Biller Jonathan | CFO | M - OptEx | $0.00 | +8,523 | 25.6K | +50% | $0 |
| D | 2022-02-23 | 2022-02-22 | AGIO | AGIOS PHARMACEUTICALS, INC. | Biller Jonathan | CFO | F - Tax | $29.08 | -2,688 | 23.0K | -10% | -$78.2K |
| D | 2022-02-14 | 2022-02-10 | AGIO | AGIOS PHARMACEUTICALS, INC. | Biller Jonathan | CFO | M - OptEx | $0.00 | +3,667 | 18.5K | +25% | $0 |
| D | 2022-02-14 | 2022-02-10 | AGIO | AGIOS PHARMACEUTICALS, INC. | Biller Jonathan | CFO | F - Tax | $31.43 | -1,349 | 17.1K | -7% | -$42.4K |
| D | 2021-12-07 | 2021-12-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | Biller Jonathan | CFO | M - OptEx | $0.00 | +5,753 | 16.6K | +53% | $0 |
| D | 2021-12-07 | 2021-12-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | Biller Jonathan | CFO | F - Tax | $35.88 | -1,823 | 14.8K | -11% | -$65.4K |
Purchase Sale Sale after option exercise All abbreviations